Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.

Authors :: Verheijen RB
Yu H
Schellens JHM
Beijnen JH
Steeghs N
Huitema ADR
Source :: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2017 Nov; Vol. 102 (5), pp. 765-776. Date of Electronic Publication: 2017 Sep 07.
Publication Year :: 2017
Abstract: Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.<br /> (© 2017 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.)

Subjects :: Dose-Response Relationship, Drug
Drug Monitoring methods
Humans
Medical Oncology methods
Neoplasms enzymology
Prospective Studies
Protein Kinase Inhibitors adverse effects
Drug Monitoring standards
Medical Oncology standards
Neoplasms drug therapy
Practice Guidelines as Topic standards
Protein Kinase Inhibitors administration & dosage

Full Text Access

Tools